Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Zeid Kuzbari(Institute of Cancer Research), Helen Hanson(University of Exeter), Sophie Allen(Institute of Cancer Research), A. Kulkarni(Guy's and St Thomas' NHS Foundation Trust), Clare Turnbull(Institute of Cancer Research), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), R. Ferrandino(European Society for Medical Oncology), Alison Garrett(University of Pittsburgh), Miika Mehine(Memorial Sloan Kettering Cancer Center), C. Benedikt Westphalen(LMU Klinikum), George J. Burghel, MF Berger(Memorial Sloan Kettering Cancer Center), Elena Castro(Research Institute Hospital 12 de Octubre), Chey Loveday(Institute of Cancer Research), Katie Snape(Institute of Cancer Research), Chaitanya Bandlamudi(Memorial Sloan Kettering Cancer Center), Angela George(Royal Marsden NHS Foundation Trust), S. Jezdic(European Society for Medical Oncology)
Cited by 133
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
|Annals of Oncology|2018|774
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|643
MicroRNA Related Polymorphisms and Breast Cancer Risk
|PLoS ONE|2014|638